Much will, however afhnge of svrvgteren Novo Nordisk, which rose a little on Monday after a dramati

Much will, however afhnge of svrvgteren Novo Nordisk, which rose a little on Monday after a dramatic decline Friday as reaction to the US lgemiddelstyrelse could not agree on recommending diabetes 2 drug Victoza.
- There will still focus on Novo Nordisk and also on Lundbeck. In addition, the companies are a bit heavy in Asia. But we're going to open a half to one per cent. higher, after increases in the US Monday in late trade, says head of Scandinavian shares in Sydbank Ole Jensen Kjr, the news agency Direkt.
A panel of experts during the American lgemiddelstyrelse, FDA, initiating at 14 o'clock a meeting where experts will look at whether they can recommend Lundbeck's schizophrenia means Serdolect. In connection with the decision as to where VRE srligt focus on substance cardiovascular mssige risks.
Shares in Lundbeck rose 0.8 percent Monday. after a drop of 3.2 per cent. Friday when the agenda for the meeting was published. Novo Monday regained 2.8 per cent. to 249.25 after a drop of 13.7 per cent. Friday. Deutsche Bank has discrete its kursml Novo's shares by 40 kr. 305 kr.
The website uses cookies to remember your settings, statistics and mlrette ads. This information is shared with third parties. Find out more about cookies OK